Glibenclamide Prevents Hypoglycemia-Induced Fatal Cardiac Arrhythmias in Rats
Candace M Reno1, Justin Bayles1, Allie Skinner1
1Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
Abstract:
Sulfonylureas increase the incidence of severe hypoglycemia in people with type 2 diabetes and might increase the risk of sudden cardiac death. Sulfonylureas stimulate insulin secretion by closing pancreatic ATP-sensitive potassium ion (KATP) channels. To investigate the role of KATP channel modulators on cardiac arrhythmias and mortality in the setting of severe hypoglycemia, adult Sprague-Dawley rats underwent hyperinsulinemic (0.2 U/kg/min) severe hypoglycemic (10 to 15 mg/dL) clamps with continuous electrocardiography. The rats were randomized for treatment with intravenous vehicle (VEH), the sulfonylurea glibenclamide (GLIB; KATP channel blocker; 5 mg/kg/h), or diazoxide (DIAZ; KATP channel opener; 5 mg/kg/h). The results demonstrated that GLIB completely prevented first-degree heart block compared with VEH (0.18 ± 0.09/min) and DIAZ (0.2 ± 0.05/min). Second-degree heart block was significantly reduced with GLIB (0.12 ± 0.1/min) compared with VEH (0.6 ± 0.2/min) and DIAZ (6.9 ± 3/min). The incidence of third-degree heart block was completely prevented by GLIB compared with VEH (67%) and DIAZ (87.5%). Hypoglycemia-induced mortality was completely prevented by GLIB compared with VEH (60%) and DIAZ (82%). In conclusion, although GLIB increases the risk of hypoglycemia by increasing insulin secretion, these results have demonstrated a paradoxical protective role of GLIB against severe hypoglycemia-induced fatal cardiac arrhythmias.
Insights
Glibenclamide, a sulfonylurea, paradoxically protected against fatal cardiac arrhythmias during severe hypoglycemia in rats. This KATP channel blocker prevented heart block and mortality, despite increasing hypoglycemia risk.
Area of Science:
- Cardiovascular Science
- Endocrinology
- Pharmacology
Background:
- Sulfonylureas are associated with severe hypoglycemia and potential cardiac risks in type 2 diabetes.
- Sulfonylureas function by closing pancreatic ATP-sensitive potassium (KATP) channels, affecting insulin secretion.
- The role of KATP channel modulators in hypoglycemia-induced cardiac events requires further investigation.
Purpose of the Study:
- To investigate the impact of KATP channel modulators on cardiac arrhythmias and mortality during severe hypoglycemia.
- To evaluate the protective effects of glibenclamide (KATP channel blocker) and diazoxide (KATP channel opener) in a rat model.
Main Methods:
- Adult Sprague-Dawley rats underwent hyperinsulinemic-hypoglycemic clamps with continuous electrocardiography.
- Rats were randomized to receive intravenous vehicle, glibenclamide (KATP channel blocker), or diazoxide (KATP channel opener).
- Cardiac arrhythmias and mortality rates were assessed under induced severe hypoglycemia.
Main Results:
- Glibenclamide completely prevented first- and third-degree heart block.
- Second-degree heart block was significantly reduced by glibenclamide compared to vehicle and diazoxide.
- Glibenclamide completely prevented hypoglycemia-induced mortality, unlike vehicle and diazoxide.
- Diazoxide exacerbated cardiac arrhythmias and mortality during hypoglycemia.
Conclusions:
- Glibenclamide exhibits a paradoxical protective effect against severe hypoglycemia-induced fatal cardiac arrhythmias.
- KATP channel blockade by glibenclamide may mitigate cardiac risks associated with severe hypoglycemia.
- These findings suggest a complex role for KATP channels in mediating cardiac outcomes during hypoglycemia.
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Hypoglycemia and Glucagon
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Cancer Prevention
Some...
Prevention of Further Absorption of Poison


